Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Tan, Roderick J ^a   Zhou, Lili ^a   Zhou, Dong ^a   Lin, Lin ^a   Liu, Youhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; COLLAGEN TYPE 1; ENDOTHELIN A RECEPTOR; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADRIAMYCIN NEPHROPATHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN 1 GENE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; GLOMERULOSCLEROSIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; TGF BETA1 GENE;

ANIMALS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FIBROSIS; GENE EXPRESSION; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MICE; PODOCYTES; PROTEINURIA; PYRROLIDINES; RECEPTOR, ENDOTHELIN A;

EID: 84893119354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079963     Document Type: Article

References (28)

1. Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91: 1-77. doi:10.1152/physrev.00060.2009. PubMed: 21248162.
2. Dhaun N, Goddard J, Webb DJ (2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955. doi:10.1681/ASN.2005121256. PubMed: 16540557.
3. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N (2012) Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 91: 490-500. doi:10.1016/j.lfs.2012.03.026. PubMed: 22480517.
4. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD et al. (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276: 473-481. PubMed: 8632312.
5. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM (2011) Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 54: 979-988. doi:10.1007/s00125-010-2021-4. PubMed: 21191784.
6. Vaněčková I, Kujal P, Husková Z, Vaňourková Z, Vernerová Z et al. (2012) Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 35: 382-392. doi:10.1159/000336823. PubMed: 22487948.
7. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F et al. (2009) Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456. doi:10.1152/ajprenal.00340.2009. PubMed: 19675181.
8. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V et al. (2011) Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 301: F1114-F1123. doi:10.1152/ajprenal.00122.2011. PubMed: 21816757.
9. Amann K, Simonaviciene A, Medwedewa T, Koch A, Orth S et al. (2001) Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 12: 2572-2584. PubMed: 11729225.
10. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T et al. (2011) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772. doi:10.1681/ASN. 2010080869. PubMed: 21372210.
11. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ et al. (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535. doi:10.1681/ASN.2009060593. PubMed: 20167702.
12. Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H et al. (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20: 655-664. doi:10.1681/ASN.2008050482. PubMed: 19144760.
13. Lee VW, Harris DC (2011) Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16: 30-38. doi:10.1111/j.1440-1797.2010.01383.x. PubMed: 21175974.
14. He W, Kang YS, Dai C, Liu Y (2011) Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 22: 90-103. doi:10.1681/ASN.2009121236. PubMed: 21030600.
15. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y (2013) Loss of Klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling. J Am Soc Nephrol 24: 771-785. doi:10.1681/ASN.2012080865. PubMed: 23559584.
16. Ding H, Zhou D, Hao S, Zhou L, He W et al. (2012) Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol 23: 801-813. doi:10.1681/ASN.2011060614. PubMed: 22302193.
17. Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. Nat. Rev Nephrol 7: 684-696. doi:10.1038/nrneph.2011.149.
18. Opocenský M, Kramer HJ, Bäcker A, Vernerová Z, Eis V et al. (2006) Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48: 965-971. doi:10.1161/01.HYP.0000245117.57524.d6. PubMed: 17015777.
19. Vanêcková I, Kramer HJ, Bäcker A, Vernerová Z, Opocensky M et al. (2005) Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46: 969-974. doi:10.1161/01.HYP.0000173426.06832.b5. PubMed: 16157796.
20. Sarafidis PA, Lasaridis AN (2010) Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy. Nat. Rev Nephrol 6: 447-449. doi:10.1038/nrneph.2010.86.
21. Yoshida Y, Fogo A, Shiraga H, Glick AD, Ichikawa I (1988) Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney Int 33: 855-867. doi:10.1038/ki.1988.77. PubMed: 3386138.
22. Patinha D, Fasching A, Pinho D, Albino-Teixeira A, Morato M et al. (2013) Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors. Am J Physiol Renal Physiol 304: F614-F622. doi:10.1152/ajprenal.00285.2012. PubMed: 23283998.
23. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I (1988) Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82: 322-330. doi:10.1172/JCI113590. PubMed: 3392211.
24. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L et al. (2005) In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166: 1309-1320. doi:10.1016/S0002-9440(10)62350-4. PubMed: 15855633.
25. Leask A (2009) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1: 115-122
26. Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP et al. (2000) Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 102: 491-493. doi:10.1161/01.CIR.102.5.491. PubMed: 10920058.
27. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK et al. (2009) ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol 53: 173-178. doi:10.1097/FJC.0b013e3181993493. PubMed: 19188829.
28. Yang KM, Russell J, Lupu ME, Cho H, Li XF et al. (2009) Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. Cancer Biol Ther 8: 1940-1946. doi:10.4161/cbt.8.20.9595. PubMed: 19717985.